Koers Apricus Biosciences Inc Nasdaq
Aandelen
US03832V1098
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2022 | - | Omzet 2023 | 2,2 2,06 | Marktkapitalisatie | 13,61 mln. 12,71 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -73 mln. -68,15 mln. | Nettowinst (verlies) 2023 | -37 mln. -34,54 mln. | EV/omzet 2022 | - |
Nettoschuld 2022 | 4,59 mln. 4,28 mln. | Nettoschuld 2023 | 11,23 mln. 10,49 mln. | EV/omzet 2023 | 11.278.476 x |
K/w-verhouding 2022 |
-0,98
x | K/w-verhouding 2023 |
-0,18
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 98,8% |
Recentste transcriptie over Apricus Biosciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 01-01-87 |
Director of Finance/CFO | 52 | 01-01-19 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 77 | 01-09-21 | |
Richard Pascoe
CHM | Chairman | 60 | 01-03-13 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 01-01-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,20% | 121 mld. | |
+19,67% | 113 mld. | |
+18,95% | 26,02 mld. | |
-23,86% | 19,39 mld. | |
-19,03% | 15,91 mld. | |
-20,90% | 15,09 mld. | |
-46,14% | 15,06 mld. | |
+63,85% | 14,93 mld. | |
+4,49% | 13,85 mld. |
- Beurs
- Aandelen
- Koers SEEL
- Koers